Sunshine Heart Changes Course Again: Pauses Neuromodulation To Focus On Aquadex
The company has switched from pursuing a counterpulsation technology to focusing on a fully implantable neuromodulation device, and is now directing its full attention to the recently acquired Aquadex FlexFlow ultrafiltration system for heart failure, all in a period of about three-to-four months.
You may also be interested in...
The heart-assist device firm abruptly announced the departure of its CEO. Sunshine has faced multiple challenges, including slow enrollment and the need for protocol-ordered pause, with the pivotal trial for its C-Pulse system.
Boston Scientific’s WaveWriter Alpha spinal cord stimulation devices feature the proprietary FAST software for rapid, paresthesia-free pain relief of chronic pain.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the final day of the meeting.